Scandion Oncology – Interim Report Q3 2022
Scandion Oncology (Scandion) today announces its interim report for Q3 2022. The following is taken from the report. Johnny Stilou, Acting CEO & CFO, comments “In the third quarter of 2022 we managed to raise approximately 42 MDKK net in a very difficult stock market. The raised capital will take us well into 2024.” Key Figures & Highlights TDKK Q3 2022 Q1-Q3 2022 Q3 2021 Q1-Q3 2021 FY 2021 Operating -23,626 -64,778 -15,392 -40,788 -55,367loss Net finance -1,447 -1,735 -359 -1,606 -1,846income/